Solutions » Imaging Core Lab Services » Therapeutic Expertise » Oncology

Oncology

Oncology Clinical Trials

In oncology clinical trials, there are many imaging endpoints that are based on the assessment of tumor size or function. These endpoints include disease-free survival, objective response rate, time to progression, progression-free survival and time to treatment failure. The analysis of these endpoints in oncology clinical trials may employ any number of scientific and regulatory rules and guidelines, including:

RECIST 1.0
RECIST 1.1
WHO Methodology
Volumetric Assessment
Cheson Criteria
Macdonald Criteria

interactive training cds for recist and cheson

Request a copy of the Cheson Criteria, RECIST 1.0 or RECIST 1.1 Interactive Training DVD

As the world leader for global, multi-center oncology clinical studies, BioClinica’s experience extends to all these criteria, often employing two or more in a single trial. The complexity of this process is not just in the number of criteria assessed, but also in the methodology selected for categorization of disease. Correct lesion identification and tracking is vital to ensure accurate and precise interpretation and on-going evaluation in oncology clinical trials.

We have expertise in all aspects of medical imaging in oncology, from diagnosis, to staging and assessment of therapeutic response. This domain knowledge is continually updated to reflect the latest developments in quantitative, semi-quantitative and qualitative image analysis. Our scientific staff is in continuous contact with the FDA to stay aware of, and implement any new regulatory guidance.